Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.895 SEK | +0.13% | -5.23% | +26.05% |
04-08 | Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board | CI |
04-04 | OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 45.62M 499M 62.36M |
---|---|---|---|---|---|
Net income 2024 * | -8M -87.52M -10.94M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 3M 32.82M 4.1M | Net cash position 2025 * | 3M 32.82M 4.1M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.73
x | P/E ratio 2025 * |
-
| Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.35% |
1 day | +0.13% | ||
1 week | -5.23% | ||
Current month | +14.56% | ||
1 month | +11.29% | ||
3 months | -48.61% | ||
6 months | +31.81% | ||
Current year | +26.05% |
Managers | Title | Age | Since |
---|---|---|---|
Stian Kildal
CEO | Chief Executive Officer | - | 23-09-12 |
Michael Owens
DFI | Director of Finance/CFO | 68 | 23-10-11 |
Markus Jerling
CTO | Chief Tech/Sci/R&D Officer | 72 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Christoph Nowak
BRD | Director/Board Member | 38 | 23-09-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.895 | +0.13% | 32,174 |
24-04-25 | 3.89 | -9.43% | 75,144 |
24-04-24 | 4.295 | +6.18% | 18,193 |
24-04-23 | 4.045 | -3.80% | 13,212 |
24-04-22 | 4.205 | +2.31% | 25,812 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+26.05% | 4.16M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ONCOZ Stock